The injected medication, liraglutide, is under review by the FDA to treat type 2 diabetes. In a study, three-quarters of patients on high doses of the drug lost 5% or more of their body weight.

Novo Nordisk's liraglutide may help thousands of patients. It may also cause thyroid cancer.Does a promising new class of diabetes drugs boost the risk of a rare thyroid tumor that may take decades to develop? Read at
http://www.forbes.com/2009/04/03/diabetes-liraglutide-novo-nordisk-busin...